Nutra Pharma Plunges to $871K Loss Amid Mounting Debt, Liquidity Crisis

TL;DR

**Nutra Pharma is a financial black hole, avoid at all costs; the company is bleeding cash and has no clear path to profitability.**

AI Summary

NUTRA PHARMA CORP. reported a net loss of $871,806 for the six months ended June 30, 2023, a significant decline from the net income of $4,367,662 in the prior year period. Total net sales increased to $106,920 for the six months ended June 30, 2023, up from $42,190 in the same period of 2022, with related party sales also rising to $212,991 from $70,386. Despite increased sales, the company's gross profit grew to $187,734 from $37,373. Operating expenses, however, remained high at $768,724 for the six months ended June 30, 2023, including $105,465 in bad debt expense from a related party. The company's accumulated deficit reached $74,423,924 as of June 30, 2023, and it faces a working capital deficit of $13,276,462 and a stockholders' deficit of $13,249,258. The change in fair value of convertible notes and derivatives swung from a gain of $5,549,845 in 2022 to a loss of $90,185 in 2023, contributing to the net loss. The company has no cash on hand as of June 30, 2023, and relies on debt and equity funding, with its common stock on the OTC Market Group's Expert Market limiting capital raising.

Why It Matters

Nutra Pharma's substantial net loss and significant accumulated deficit raise serious red flags for investors, indicating a company struggling with financial viability. The reliance on debt and equity funding, coupled with its common stock being relegated to the OTC Expert Market, severely limits its ability to raise necessary capital, putting its future operations at risk. For employees, this financial instability could signal job insecurity, while customers might face uncertainty regarding product availability and support. In a competitive biotechnology and consumer health market, Nutra Pharma's inability to achieve profitability and its precarious liquidity position make it a high-risk investment, potentially impacting broader market sentiment for micro-cap biotech firms.

Risk Assessment

Risk Level: high — The company has an accumulated deficit of $74,423,924, a working capital deficit of $13,276,462, and a stockholders' deficit of $13,249,258 as of June 30, 2023. Furthermore, it has no cash on hand and its common stock is on the OTC Market Group's Expert Market, severely limiting its ability to raise capital, indicating substantial doubt about its ability to continue as a going concern.

Analyst Insight

Investors should avoid NUTRA PHARMA CORP. given its severe liquidity issues, recurring losses, and substantial accumulated deficit. The company's inability to generate sufficient cash from operations and its limited access to capital markets make it a highly speculative and risky investment.

Financial Highlights

debt To Equity

N/A

revenue

$106,920

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$871,806

eps

N/A

gross Margin

175.6%

cash Position

$0

revenue Growth

+153.4%

Revenue Breakdown

Key Numbers

• $871,806 — Net loss for six months ended June 30, 2023 (Significant decline from $4,367,662 net income in prior year)
• $74,423,924 — Accumulated deficit as of June 30, 2023 (Indicates substantial historical losses)
• $13,276,462 — Working capital deficit as of June 30, 2023 (Highlights severe short-term liquidity issues)
• $13,249,258 — Stockholders' deficit as of June 30, 2023 (Indicates liabilities exceed assets)
• $0 — Cash as of June 30, 2023 (Company has no cash on hand)
• $106,920 — Net sales for six months ended June 30, 2023 (Increased from $42,190 in 2022, but still low)
• $212,991 — Net sales to a related party for six months ended June 30, 2023 (Increased from $70,386 in 2022)
• $768,724 — Total operating expenses for six months ended June 30, 2023 (Remains high despite low revenue)
• $90,185 — Loss from change in fair value of convertible notes and derivatives for six months ended June 30, 2023 (Swing from a $5,549,845 gain in 2022)
• 7,099,727,214 — Shares of common stock issued and outstanding as of October 23, 2025 (High share count relative to company value)

Key Players & Entities

• NUTRA PHARMA CORP. (company) — registrant
• ReceptoPharm, Inc. (company) — wholly-owned subsidiary
• Designer Diagnostics Inc. (company) — wholly-owned subsidiary, inactive since June 2011
• OTC Market Group's Expert Market (regulator) — market where common stock is traded, limiting capital raising
• Cobroxin (product) — over-the-counter pain reliever launched October 2009
• Nyloxin (product) — over-the-counter pain reliever launched May 2010
• Pet Pain-Away (product) — over-the-counter pain reliever launched December 2014
• Equine Pain-Away (product) — over-the-counter topical pain reliever launched October 2019
• Luxury Feet (product) — over-the-counter pain reliever launched March 2021
• Cell Defender (product) — zeolite detoxifier manufactured for a third party distributor since October 2021

FAQ

Risk Factors

• Severe Liquidity Constraints [high — financial]: The company has a working capital deficit of $13,276,462 and no cash on hand as of June 30, 2023. This severe lack of liquidity poses an immediate threat to its ability to meet short-term obligations.
• Substantial Accumulated Deficit [high — financial]: The accumulated deficit stands at $74,423,924 as of June 30, 2023, reflecting a history of significant unprofitability. This deep deficit indicates a long-standing inability to generate sustainable profits.
• Reliance on Debt and Equity Funding [high — financial]: With no cash reserves, the company is entirely dependent on external debt and equity financing. The limited trading venue (OTC Market Group's Expert Market) for its common stock likely hinders its ability to raise capital effectively.
• High Operating Expenses Relative to Revenue [high — operational]: Total operating expenses were $768,724 for the six months ended June 30, 2023, significantly exceeding the net sales of $106,920. This indicates a highly inefficient operational structure.
• Significant Bad Debt Expense from Related Party [medium — financial]: The company incurred $105,465 in bad debt expense from a related party. This raises questions about the creditworthiness of related party transactions and potential conflicts of interest.
• Adverse Change in Fair Value of Financial Instruments [medium — financial]: The change in fair value of convertible notes and derivatives swung from a gain of $5,549,845 in the prior year to a loss of $90,185 for the six months ended June 30, 2023. This volatility directly impacts net income and financial stability.
• Limited Trading Liquidity and Investor Access [medium — market]: The company's common stock trades on the OTC Market Group's Expert Market. This limited trading environment can restrict investor access, reduce liquidity, and make capital raising more challenging.
• Stockholders' Deficit [high — financial]: A stockholders' deficit of $13,249,258 as of June 30, 2023, signifies that total liabilities exceed total assets, indicating negative equity and a precarious financial position.

Industry Context

The pharmaceutical and nutraceutical industries are highly competitive and capital-intensive, requiring significant investment in research, development, and regulatory compliance. Companies often face challenges in bringing products to market and achieving profitability due to long development cycles, patent expirations, and stringent regulatory hurdles. The market is characterized by both large, established players and numerous smaller, emerging companies vying for market share.

Regulatory Implications

Nutra Pharma Corp operates within a heavily regulated industry. Compliance with FDA and other health authority regulations is paramount for product approval, manufacturing, and marketing. Failure to adhere to these regulations can result in product recalls, fines, and reputational damage, significantly impacting financial performance and market access.

What Investors Should Do

1. Scrutinize Related Party Transactions
2. Assess Path to Profitability
3. Monitor Capital Raising Efforts
4. Evaluate Operational Efficiency

Key Dates

• 2023-06-30: Six months ended June 30, 2023 — Reported a net loss of $871,806 and a working capital deficit of $13,276,462, with zero cash on hand.
• 2022-06-30: Six months ended June 30, 2022 — Reported a net income of $4,367,662, a significant turnaround from the current period's loss.

Glossary

Accumulated Deficit

The total cumulative net losses of a company that have not been offset by net income or other gains since its inception. (Indicates Nutra Pharma Corp has a long history of unprofitability, with a deficit of $74,423,924 as of June 30, 2023.)

Working Capital Deficit

Occurs when a company's current liabilities exceed its current assets, indicating a potential inability to meet short-term obligations. (Nutra Pharma Corp has a significant working capital deficit of $13,276,462 as of June 30, 2023, highlighting severe liquidity issues.)

Stockholders' Deficit

A negative equity position where a company's total liabilities exceed its total assets. (Nutra Pharma Corp has a stockholders' deficit of $13,249,258 as of June 30, 2023, indicating its liabilities outweigh its assets.)

Fair Value of Convertible Notes and Derivatives

The market value of financial instruments that can be converted into equity or are linked to underlying assets, subject to market fluctuations. (A swing from a gain of $5,549,845 to a loss of $90,185 for this item in the six months ended June 30, 2023, significantly impacted the company's net results.)

Bad Debt Expense

An expense recognized for accounts receivable that are deemed uncollectible. (The company recorded $105,465 in bad debt expense from a related party, raising concerns about transaction quality.)

Year-Over-Year Comparison

Compared to the prior year period, Nutra Pharma Corp. has seen a significant deterioration in its financial performance. While net sales increased by 153.4% to $106,920 for the six months ended June 30, 2023, the company swung from a net income of $4,367,662 to a net loss of $871,806. Gross profit improved significantly, but this was overshadowed by high operating expenses and a negative swing in the fair value of financial instruments. The company's liquidity position has worsened dramatically, with zero cash on hand and substantial working capital and stockholders' deficits, indicating a much more precarious financial state than in the previous reporting period.

Filing Documents

• form10-q.htm (10-Q) — 1805KB
• ex31-1.htm (EX-31.1) — 19KB
• ex32-1.htm (EX-32.1) — 7KB
• 0001493152-25-019037.txt ( ) — 10760KB
• nphc-20230630.xsd (EX-101.SCH) — 66KB
• nphc-20230630_cal.xml (EX-101.CAL) — 70KB
• nphc-20230630_def.xml (EX-101.DEF) — 314KB
• nphc-20230630_lab.xml (EX-101.LAB) — 510KB
• nphc-20230630_pre.xml (EX-101.PRE) — 431KB
• form10-q_htm.xml (XML) — 1762KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION F-1

Financial Statements

Item 1. Financial Statements F-1 Condensed Consolidated Balance Sheets as of June 30, 2023 (Unaudited) and December 31, 2022 F-1 Condensed Consolidated Statements of Operations for the Three and Six months ended June 30, 2023 and 2022 (Unaudited) F-2 Condensed Consolidated Statements of Changes in Stockholders' Deficit for the Three months ended June 30, 2023 and 2022 (Unaudited) F-3 Condensed Consolidated Statements of Changes in Stockholders' Deficit for the Six months ended June 30, 2023 and 2022 (Unaudited) F-4 Condensed Consolidated Statements of Cash Flows for the Six months ended June 30, 2023 and 2022 (Unaudited) F-5 Notes to Condensed Consolidated Financial Statements (Unaudited) F-6

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 4

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 10

Controls and Procedures

Item 4. Controls and Procedures 10

OTHER INFORMATION

PART II. OTHER INFORMATION 11

Legal Proceedings

Item 1. Legal Proceedings 11

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 12

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 12

Mine Safety Disclosure

Item 4. Mine Safety Disclosure 12

Other Information

Item 5. Other Information 12

Exhibits

Item 6. Exhibits 12 2 Nutra Pharma Corp ("Nutra Pharma") and its wholly owned subsidiary, ReceptoPharm, Inc. ("ReceptoPharm"), are referred to herein as "we", "our" or "us" (ReceptoPharm is also individually referred to herein). Forward Looking Statements This Quarterly Report on Form 10–Q for the period ending June 30, 2023, contains forward–looking statements that involve risks and uncertainties, as well as assumptions that if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward–looking statements. The words or phrases "would be," "will allow, "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward–looking statements." We are subject to risks detailed in Item 1(a). All statements other than statements of historical fact are statements that could be deemed forward–looking statements, including: (a) any projections of revenue, gross margin, expenses, earnings or losses from operations, synergies or other financial items; and (b) any statements of the plans, strategies and objectives of management for future operations; and (c) any statement concerning developments, plans, or performance. Unless otherwise required by applicable law, we do not undertake and we specifically disclaim any obligation to update any forward–looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement. 3 PART I. FINANCIAL INFORMATION Item 1. Financial Statements NUTRA PHARMA CORP. Condensed Consolidated Balance Sheets June 30, December 31, 2023 2022 (Unaudited) ASSETS Current assets: Cash $ - $ - Accounts receivable 21,754 21,664 Inventory, current portion 29,945 23,866 Convertible notes receivable, net of discount - 225,396 Settlement receivable 264,000 - Prepaid expenses and oth

View Full Filing

View this 10-Q filing on SEC EDGAR